美股A股
StockGist
Back
10-Q2026-05-13· deepseek-chat

STAA · STAAR Surgical Company

0000718937-26-000023

SEC filing

Summary

A transformative quarter: revenue surged 120% as China sales rebounded, driving profitability and a return to net income, though operating cash flow turned negative on working capital.

Key takeaways

Full analysis

China Rebound Drives Record Revenue Growth

Margin Expansion and Profitability Turnaround

Cash Flow and Liquidity Considerations

Outlook and Strategic Positioning

Future capital requirements will depend on many factors, including the growth rate in net sales, the timing and extent of spending to support the growth strategy, the expansion of selling and marketing activities, the timing of introductions of new products, and global macroeconomic factors. If anticipated future cash flow from operating activities is insufficient to satisfy future capital requirements in the long term, the company may need to seek additional capital. The EVO+ ICL, which carries a premium selling price, supports potential margin expansion as production volumes increase over time.